Skip to contentS
Sunshine Biopharma Inc.
S
SBFMSunshine Biopharma Inc. Q1 2024 · 10-Q
Revenue$7.54M$7.54M+54.1% vs Q1 2023 Net Income-$1.28M-$1.28MN/M vs Q1 2023 EPS Diluted-$2.00-$2.00N/M vs Q1 2023 Gross Profit$2,354,337+28.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sunshine Biopharma Inc. · CIK 1402328 · Engraved from SEC EDGAR
Operating Cash Flow-$3,185,158N/M Free Cash Flowderived-$3,248,095— Margins · derivedGross margin31.2%−6.1 pt vs Q1 2023
Operating margin-17.9%+19.5 pt vs Q1 2023
Net margin-17.0%+17.8 pt vs Q1 2023
ended Mar 31, 2024 · filed May 20, 2024 · 50 d after period end